scholarly journals In Vitro Activity of the New Glycopeptide LY333328 against Multiply Resistant Gram-Positive Clinical Isolates

1998 ◽  
Vol 42 (9) ◽  
pp. 2452-2455 ◽  
Author(s):  
Fernando García-Garrote ◽  
Emilia Cercenado ◽  
Luis Alcalá ◽  
Emilio Bouza
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Resistant Strains

ABSTRACT The in vitro activity of LY333328 was compared with those of vancomycin and teicoplanin against 425 gram-positive clinical isolates, including a variety of multiply resistant strains. LY333328 at ≤4 μg/ml inhibited all microorganisms tested, including methicillin- and teicoplanin-resistant staphylococci, glycopeptide-resistant enterococci, penicillin- and multiply resistant pneumococci, and viridans and beta-hemolytic streptococci.

scholarly journals 1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S655-S655
Author(s):  
Daniel Navas ◽  
Angela Charles ◽  
Amy Carr ◽  
Jose Alexander
Keyword(s):  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Resistance Testing ◽  
Clinical Samples ◽  
In Vitro Activity ◽  
Carbapenemase Gene ◽  
Resistant Strains

Abstract Background The activity of imipenem/relebactam (I/R), ceftazidime/avibactam (CZA) and cefiderocol (FDC) were evaluated against clinical isolates of multidrug resistant (MDR) strains of P. aeruginosa which was resistant to ceftolozane/tazobactam (C/T). The recent increase of MDR P. aeruginosa strains isolated from clinical samples has prompted research and development of new antimicrobials that can withstand its multiple resistance mechanisms. C/T is an effective option for treatment of MDR P. aeruginosa in our facility with only 10% of resistance in MDR strains, but the emergence of resistance may occur due to the presence of a carbapenemase gene or an ampC mutation. Methods Antimicrobial susceptibility testing for C/T Etest® (bioMérieux, Inc.) were performed on all MDR strains initially screened by the VITEK2® (bioMérieux, Inc.). 10% (n=20) of all MDR isolates were resistant to C/T by the CLSI 2019 breakpoints. These resistant isolates were tested for presence of a carbapenemase gene using the GeneXpert CARBA-R (Cepheid®) PCR and against CZA Etest® (bioMérieux, Inc.) I/R gradient strips (Liofilchem®) and FDC broth microdilution (Thermo Scientific™ Sensititre™). Results A total of 20 clinical isolates of MDR P. aeruginosa resistant to C/T were tested following standardized CLSI protocols and techniques. All 20 isolates were screened for the presence of a carbapenemase gene (blaVIM, blaNDM, blaKPC, blaOXA-48, blaIMP). A blaVIM gene was detected in 6 (30%) out of 20 isolates. FDC demonstrated the greatest activity with 85% (n=17) of susceptible isolates (CLSI MIC <4µg/dL). CZA (CLSI MIC <8µg/dL) and I/R (FDA MIC <2µg/dL) showed 15% (n=3) and 10% (n=2) of susceptible isolates respectively. FDC was active against all 6 blaVIM isolates, where all 6 strains were resistant to CZA and I/R as expected. 3 isolates tested non-susceptible against FDC; additional characterization was not performed at this time. Conclusion Based on these results, FDC demonstrated the greatest in-vitro activity against C/T resistant strains of MDR P. aeruginosa. FDC also demonstrated activity against all 6 MDR P. aeruginosa carrying blaVIM gene. FDC is a strong option to consider on MDR P. aeruginosa strains based on a resistance testing algorithm and a cost/effective protocol. Disclosures All Authors: No reported disclosures

scholarly journals In vitro activity of tigecycline against 313 Gram-positive and Gram-negative clinical isolates

2010 ◽  
Vol 25 (1) ◽  
Author(s):  
Elisabetta Maioli ◽  
Erika Coppo ◽  
Ramona Barbieri ◽  
Elisabetta Canepa ◽  
Laura Gualco ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative

In vitro Activity of Quinupristin/ Dalfopristin, RP59500, against Gram-Positive Clinical Isolates

Chemotherapy ◽  
1997 ◽  
Vol 43 (2) ◽  
pp. 94-99 ◽  
Author(s):  
Hussain Qadri ◽  
Y. Ueno ◽  
Abu Mostafa ◽  
Majid Halim
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive

scholarly journals In vitro activity of RU 64004, a new ketolide antibiotic, against gram-positive bacteria.

1997 ◽  
Vol 41 (5) ◽  
pp. 1196-1202 ◽  
Author(s):  
T Schülin ◽  
C B Wennersten ◽  
R C Moellering ◽  
G M Eliopoulos
Keyword(s):  
Vitro Activity ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Positive Bacteria ◽  
Agar Dilution ◽  
Resistant Strains ◽  
Erythromycin A

The comparative in vitro activity of RU 64004 (also known as HMR 3004), a new ketolide antibiotic, was tested by agar dilution against approximately 500 gram-positive organisms, including multiply resistant enterococci, streptococci, and staphylococci. All streptococci were inhibited by < or = 1 microg of RU 64004 per ml. The ketolide was more potent than other macrolides against erythromycin A-susceptible staphylococci and was generally more potent than clindamycin against erythromycin A-resistant strains susceptible to this agent. Clindamycin-resistant staphylococci (MIC, > 128 microg/ml) proved resistant to the ketolide, but some erythromycin A- and clindamycin-resistant enterococci remained susceptible to RU 64004.

scholarly journals In vitro activity of telavancin against recent Gram-positive clinical isolates: results of the 2004-05 Prospective European Surveillance Initiative

2008 ◽  
Vol 62 (1) ◽  
pp. 116-121 ◽  
Author(s):  
D. C. Draghi ◽  
B. M. Benton ◽  
K. M. Krause ◽  
C. Thornsberry ◽  
C. Pillar ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive

In vitro Activity of Biapenem against Recent Gram-Negative and Gram-Positive Clinical Isolates

Chemotherapy ◽  
1997 ◽  
Vol 43 (6) ◽  
pp. 393-399 ◽  
Author(s):  
Giovanni Bonfiglio ◽  
Giuseppa Maccarone ◽  
Maria Lina Mezzatesta ◽  
Angela Privitera ◽  
Vincenzo Carciotto ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Negative

In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan

1999 ◽  
Vol 33 (4) ◽  
pp. 299-303 ◽  
Author(s):  
Shan-Chwen Chang ◽  
Chi-Tai Fang ◽  
Po-Ren Hsueh ◽  
Kwen-Tay Luh ◽  
Wei-Chuan Hsieh
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive ◽  
Gram Positive Bacteria

scholarly journals Dalbavancin In Vitro Activity Obtained Against Gram-Positive Clinical Isolates Causing Osteomyelitis in US Hospitals (2011–2015)

2016 ◽  
Vol 3 (suppl_1) ◽  
Author(s):  
Rodrigo E. Mendes ◽  
Robert K. Flamm ◽  
Michael Pfaller ◽  
Mariana Castanheira ◽  
Helio S. Sader
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive

scholarly journals In Vitro Activity of Novel Rifamycins against Gram-positive Clinical Isolates

2007 ◽  
Vol 60 (9) ◽  
pp. 572-576 ◽  
Author(s):  
Christopher K Murphy ◽  
Elena Karginova ◽  
Dan Sahm ◽  
David M Rothstein
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Gram Positive
Sign in / Sign up

Export Citation Format

Share Document